BBV152

Step by step.... Till fruition

[Ocugen @Ocugen]

Early #OCU410ST results show:
✓ 54% reduction in atrophic lesion growth
✓ 100% of treated eyes stabilized or improved
✓ +6 letter gain in visual acuity

Hear from an OCU410ST clinical trial participant: https://t.co/znh5I8UL9R

$OCGN

[Ocugen @Ocugen]

What makes #OCU400 different?

OCU400 is designed to address multiple RP mutations through a potential one-time therapy.

Follow us for updates as we advance OCU400 toward a planned BLA submission this year.

#RetinitisPigmentosa #GeneTherapy $OCGN

[Ocugen @Ocugen]

100,000+ people with #Stargardtdisease have no FDA approved treatment. #OCU410ST aims to slow or stop disease progression, with early promising data.

Follow Ocugen and be part of something groundbreaking. #Biotech #Genetherapy $OCGN

[Ocugen @Ocugen]

What is #Stargardtdisease?

A rare inherited retinal disease that can cause central vision loss, often beginning early in life. Ocugen’s investigational #genetherapy candidate, #OCU410ST, is designed to target disease pathways. #Biotech $OCGN

[BBV152 @BBV152]

$OCGN Momentum truly is building

[Ocugen @Ocugen]

Momentum continues at Ocugen. With $130 million in financing secured, we are well-positioned to advance our three late-stage
programs as we work toward filing three BLAs by 2028.

Learn more: https://t.co/7nSj5EJkPZ

#GeneTherapy #Biotech #FinancialUpdate $OCGN

[BBV152 @BBV152]

$OCGN May the 4th be with us!

[Ocugen @Ocugen]

What is the Ellipsoid Zone (EZ)? EZ is a structural biomarker for photoceptor integrity which correlates to visual function. Share this with someone who should know more about EZ.

#EyeHealth #Biotech #Retina #Ophthalmology #AMD #StargardtDisease

[BBV152 @BBV152]

$OCGN And yeah... I added 🤖

[BBV152 @BBV152]

$OCGN A lot of mixed feelings going around. I still trust & believe in the company, its products, and their ability to succeed under exceeding pressure and odds. Breaking into a healthcare system already established in the US by giants, all within a matter of years. On the brink

[BBV152 @BBV152]

$OCGN A lot of mixed feelings going around. I still trust & believe in the company, its products, and their ability to succeed under exceeding pressure and odds. Breaking into a healthcare system already established in the US by giants, all within a matter of years. On the brink

[Ocugen @Ocugen]

Honored to join the U.S. @CommerceGov Certified Trade Mission to Singapore with https://t.co/MFNdMesYmg, connecting with investors and industry leaders to advance cross-border collaboration. Looking forward to continuing the conversation globally. @drsmusunuri #TradeMission

[Ocugen @Ocugen]

Phase 2 Update: A 31% reduction in GA lesion growth was observed with #OCU410 (medium dose) and a 27% EZ preservation in treated v. control supporting medium dose as optimal in Phase 3. #GeographicAtrophy #PatientImpact

Latest corp. presentation: https://t.co/hIYAlBqgZQ

[Ocugen @Ocugen]

#OCU410 Phase 2 ArMaDa topline results show:
• 31% ↓ GA lesion growth at 12 months vs. control
• ~2X treatment effect vs. approved therapies
• EZ preservation + favorable safety
A one-and-done approach to reduce treatment burden.
🔗https://t.co/hIYAlBqgZQ #GeographicAtrophy

[BBV152 @BBV152]

$OCGN Keep the stories coming #Ocugen! It's the patients that truly matter, and hearing their stories are nothing short of amazing. Looking forward to many more success stories as your products continue to show us what we never thought was possible! 👏

[Ocugen @Ocugen]

Elaynna, an #OCU410ST trial participant, describes the procedure as seamless and the team as supportive after completing treatment for #Stargardtdisease. Now in Phase 2/3, GARDian3 is studying its potential to slow or stop progression. Phase 1 results: https://t.co/h8YBzcXc7k

[BBV152 @BBV152]

$OCGN It's stories like these that make me so excited to be invested in #Ocugen! The impact their treatments are going to have in people's lives can't be understated. I look forward to hearing many more stories like this as their treatment gets approved 🙏
https://t.co/YF0Hi6wV0f

[Ocugen @Ocugen]

With the successful completion of enrollment in the GARDian3 Phase 2/3 pivotal trial for Stargardt disease, Ocugen expects to file BLA by mid-2027.

Read more: https://t.co/GdGaVwoRnw

#Stargardt #GeneTherapy #InheritedRetinalDiseases #BlindnessDiseases

[BBV152 @BBV152]

$OCGN Another completed trial 🎉 Time to start the countdown ⏱️ https://t.co/MkTZhGnYer

[Ocugen @Ocugen]

Our one-time gene therapies target 100s of mutations and address the $132B annual burden of #visionloss. “Probably 100 years from now, they’ll say #genetherapy was one of the greatest discoveries of the 21st century.” – CEO @drsmusunuri in @PharmaVoice
https://t.co/jSfXQSmqz1

[BBV152 @BBV152]

$OCGN I just buy more on days like today

[BBV152 @BBV152]

$OCGN Just a reminder...

[Ocugen @Ocugen]

Today, CEO @drsmusunuri shares encouraging 12-month Phase 2 results for #OCU410 in GA, showing impact on lesion growth and visual function. A one-time gene therapy approach with potential to shift the landscape and address unmet needs.

Read more: https://t.co/T8wJP0hsS7